21053 Case Study - Altmetric Neurocrine Biosciences WEB2.pdf (187.63 kB)
How Neurocrine Biosciences used altmetrics to measure success
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.
For nearly three decades, Neurocrine Biosciences has specialized in FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids and clinical programs in multiple therapeutic areas.
Chirag Shah, Head of Publications Strategy and
Office of Grants/Education at Neurocrine Biosciences, spoke to us about how altmetrics were particularly helpful in the therapeutic area of tardive dyskinesia (TD)
